Recent Developments in Heterocyclic Derivatives as Novel Cancer Therapeutics: From 2020-2024.

Despite progress in cancer research, cancer continues to be a leading cause of mortality worldwide; hence, therapeutic strategies must constantly improve. Drug discovery has revealed that heterocyclic moieties are fundamental and unique scaffolds because of their structural versatility and ability to interact with key biological targets. In these cyclic compounds, heteroatoms are a signature that serves to modulate cellular pathways relevant to tumor progression, apoptosis, and proliferation. Hybridization between the aromatic ring and the non-aromatic ring in a heterocyclic structure has resulted in the development of novel heterocyclic derivatives with increased anticancer activity, increased selectivity, and reduced adverse effects in the clinic, and has recently been used extensively in medicinal chemistry. Research has been directed towards the improvement of their molecular frameworks and integration of computational modelling for drug design, as well as advanced drug delivery systems to improve their therapeutic potential. As this field is progressing rapidly, this review attempts to comprehensively analyze the role of heterocyclic moieties in the development of anticancer drugs, the latest advances, and prospects. This study will contribute to ongoing efforts to design more effective and targeted cancer therapies by summarizing key findings and emerging trends.